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Abstract
Intracellular proteins have a great potential as targets for therapeutic antibodies (Abs) but the plasma membrane prevents
access to these antigens. Ab fragments and IgGs are selected and engineered in E. coli and this microorganism may be also
an ideal vector for their intracellular delivery. In this work we demonstrate that single-domain Ab (sdAbs) can be engineered
to be injected into human cells by E. coli bacteria carrying molecular syringes assembled by a type III protein secretion
system (T3SS). The injected sdAbs accumulate in the cytoplasm of HeLa cells at levels ca. 10
5–10
6 molecules per cell and
their functionality is shown by the isolation of sdAb-antigen complexes. Injection of sdAbs does not require bacterial
invasion or the transfer of genetic material. These results are proof-of-principle for the capacity of E. coli bacteria to directly
deliver intracellular sdAbs (intrabodies) into human cells for analytical and therapeutic purposes.
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Introduction
The ability to express antibody (Ab) fragments in Escherichia coli
has an enormous biotechnological and therapeutic potential [1].
The smallest Ab fragments (,12–15 kDa) are the so-called single-
domain antibodies (sdAbs), which are composed of a single
variable (V) immunoglobulin (Ig) domain [2,3]. The sdAbs are
generated by engineering conventional Igs (e.g. human or murine)
[4] or obtained from natural heavy-chain-only Igs expressed by
certain animals like camelids [5]. The sdAbs from camelid heavy-
chain-only Igs are known as VHH domains or Nanobodies.
Importantly, the absence of a paired V domain in VHHs does not
hinder their affinity for their cognate antigens, which is in the same
range of conventional Abs with paired VH/VL domains
(KD,10
28–10
210 M). Targets for therapeutic Abs are extracellu-
lar including cytokines, matrix proteins, and extracellular domains
of membrane receptors [6]. Intracellular proteins (e.g. components
of cell signaling cascades) are excellent therapeutic targets but
plasma membrane prevents the access of Abs to them. Nonethe-
less, Ab fragments against different antigens have been expressed
intracellularly (intrabodies) as inhibitors of proteins involved, for
instance, in carcinogenesis and viral replication [7,8]. Intrabody
expression requires transfer of the encoding gene into the cell,
either using transfection with naked DNA, liposomes, or infection
with recombinant viral vectors, which raises concerns given its
possible integration into the host cell genome. Therefore direct
transfer of antibody polypeptides into target cells constitute an
attractive alternative. Since E. coli is employed for selection,
engineering and production of IgGs and Ab fragments [9,10] this
microorganism is an excellent candidate for delivery of intrabo-
dies. Preferably, the delivery system should avoid the use of
invasive E. coli strains that release their cell content after lysis in the
phagosome [11]. Interestingly, intestinal pathogenic E. coli strains,
such as the enteropathogenic E. coli (EPEC) O127:H6 [12] and
enterohaemorragic E. coli (EHEC) O157:H7 [13], remain
extracellular while using a type III protein secretion system
(T3SS) to inject specific bacterial proteins, referred to as
‘‘effectors’’, into mammalian cells [14,15].
EPEC and EHEC adhere to enterocytes in the gastrointestinal
tract while inducing characteristic ‘‘attachment and effacement’’
(A/E) lesions [16]. A chromosomal pathogenicity island of 35–
40 kb, called the locus of enterocyte effacement (LEE)[17], encodes
the proteins responsible of A/E lesion formation, including the
outer membrane adhesin intimin (eae), the T3SS, and six effectors
[18].T3SSsaresupramolecularproteinassembliesembedded inthe
bacterial envelope (called the needle complex or injectisome). They
are composed of a cytosolic ATPase, inner and outer membrane
rings, a periplasmic shaft and an extracellular needle [19,20].
Protein translocation is dependent on insertion of hydrophilic
translocation pore into the plasma membrane of the eukaryotic cell
(the translocon) [19]. In EPEC and EHEC the needle complex is
extended up to 700 nm by long and flexible EspA filament of
polymerized EspA and the translocon is composed of translocated
proteins EspB and EspD [21].
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non-cleavable N-terminal translocation signal usually comprising
the first ,15–30 residues [20,22]. N-terminal fusions of effectors
with viral antigens and certain enzymes have been secreted
through T3SSs for the generation of live vaccines [23,24] or as
translocation reporters [25,26]. The aim of this study was to
determine whether non-invasive E. coli bacteria carrying a T3SS
can be used to translocate Ab fragments into human cells.
Results
Secretion of functional sdAbs into E. coli culture media
The N-terminal 20 amino acids of the effector EspF, which are
fully conserved in EPEC strain E2389/69 and EHEC strain
EDL933stx (Table 1), were selected to drive the T3 secretion of the
sdAb fragments. We chose VHHs as sdAb fragments due to their
favorable biophysical properties and ability to function as potent
enzyme inhibitors [5,27]. Two characterized VHHs, named Vamy
and Vgfp, recognizing amylase (Amy) and the green fluorescent
protein (GFP) respectively, were employed as models [28,29]. We
used the IPTG-inducible bacterial expresion vector pSA10
(Table 2) to express EspF20 T3 signal (T3s) fused to Vamy
(T3sVamy) or Vgfp (T3sVgfp) (Fig. S1). The VHHs were tagged
with His and E-tag epitopes at their C-termini to allow metal-
affinity purification and detection with monoclonal antibodies
(mAbs). Although T3SS are cell-contact dependent, secretion can
be triggered in vitro under by growing bacteria under certain
growth conditions [20]. In EPEC this is achieved by growth in
DMEM 5% CO2 at 37uC. Thus, we used this growth conditions to
analyze whether T3sVHHs are secreted by the T3SS of EPEC
(Fig. 1). EPEC wild-type (wt) strain and DescN strain (Table 1),
which lacks the T3SS ATPase EscN [30], transformed with pSA10
(empty vector), pT3sVamy, or pT3sVgfp, were grown in DMEM
and induced with IPTG for 3 h. Induction of T3sVHH fusions did
not affect the growth of EPEC strains, which reached the same
final optical density (OD600 nm,1.2) as cultures with the empty
vector. Coomassie staining of proteins secreted from wt EPEC
revealed discrete bands corresponding to the T3SS substrates (e.g.
EspA, EspB, EspD) and protein bands of ca. 21–23 kDa,
corresponding to the expected size of T3sVHHs, when bacteria
carried pT3sVamy or pT3sVgfp (Fig. 1B; lanes 1–3). No secreted
T3sVHHs were seen from wt EPEC carrying the empty vector.
Neither protein bands corresponding to the T3SS substrates nor
the T3sVHHs were present in the supernatant of DescN strain
(Fig. 1B; lanes 4–6). A band corresponding to the autotransporter
EspC [31], which is secreted by the Sec-pathway, was present in
the supernatants of both the wt and DescN strains.
We next evaluated expression and secretion of the T3sVHHsb y
Western blot (WB). The anti-E-tag mAb detected the T3sVHHs( c a .
21–23 kDa) in the culture supernatants of wt EPEC but not in the
DescN strain containing pT3sVamy and pT3sVgfp (Fig. 1C; top
panel;lanes 1–6). In contrast,T3sVHHs were detected in the bacterial
lysates of both the wt and DescN strains with these plasmids (Fig. 1C;
lanes7–12).Themembraneswerealsoprobedwithanti-GroELmAb
(Fig. 1C; bottom panels) to control for non-specific release of
cytoplasmic EPEC proteins. The result showed no reactivity with
anti-GroEL in culture supernatants (lanes 1–6) whereas strong signals
were detected in bacterial lysates (lanes 7–12). Secretion of the
Table 1. E. coli strains employed in this study.
Strain Relevant genotype and features Reference
E. coli JM109 K-12 l-, supE44 thi1 mcrA recA1 endA1 hsdR17 gyrA96 relA1 Dlac-proAB, F’ (traD36 proAB lacIq lacZDM15)/cloning strain [69]
EPEC E2348/69 wild type enteropathogenic EPEC O127:H6 [12]
EPEC DescN E2348/69 DescN::Km/mutant lacking EscN ATPase of the T3SS [37,70]
EHEC EDL933stx wild type enterohaemorragic EHEC O157:H7 stx1- stx2- [13,70]
EHEC DescN EDL933stx DescN::Km/mutant lacking EscN ATPase of T3SS [70]
quad mutant E2348/69 Deae Dtir Dmap DespF/attenuated strain [34]
doi:10.1371/journal.pone.0015227.t001
Table 2. Plasmids employed in this study.
Name Relevant features and application Reference
pSA10 Ap
r, pUC-ori, Ptac promoter, lacI
q/expression vector [72]
pT3sVamy pSA10 derivative/expression of T3sVamy This work
pT3sVgfp pSA10 derivative/expression of T3sVgfp This work
pDsVgfp pSA10 derivative/expression of DsVgfp; lacks T3 signal (EspF20) This work
pCX340 Tc
r, pBR-ori; Ptrc promoter, ‘blaM (TEM-1)/ vector for b-lactamase fusions [26]
pT3s-Bla pCX340 derivative/expression of T3s-Bla fusion This work
pT3sVgfp-Bla pCX340 derivative/expression of T3sVgfp-Bla fusion This work
pT3sVamy-Bla pCX340 derivative/expression of T3sVamy-Bla fusion This work
pEGFP-N1 Km
r, pUC/pSV40-ori, PCMV promoter, enhanced GFP Clontech
pCS2+MT Ap
r, pUC-ori, PCMV promoter, 6xmyc-tag, vector [74]
doi:10.1371/journal.pone.0015227.t002
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strain but not in the EHEC DescN strain (Fig. S2; Table 1). As an
additional proof of the T3-dependent secretion, a derivative of
pT3sVgfp was constructed in which the T3s was deleted (pDsVgfp).
WB of induced wt EPEC and EHEC carrying pDsVgfp resulted in
intracellular accumulation of Ds V g f pb u tn o ti ni t ss e c r e t i o n( F i g .S 3 ) .
To determine whether secreted T3sVHHsr e m a i n e da ss o l u b l e
proteins, and to rule out their aggregation or association with outer
membrane vesicles (OMVs), the culture supernatants from induced
EPEC were ultracentrifuged at 100,000 g. The presence of T3sVHHs
in the soluble and pellet fractions was analyzed by WB (Fig. S4)
showing that $95% of T3sVHHsa r ef o u n da ss o l u b l ep r o t e i n s .
Figure 1. Secretion of sdAbs to the extracellular medium with T3SS of EPEC. (A) Schematic representation of the T3SS-complex encoded
by EPEC, labeling the essential ATPase EscN, the extracellular EspA filament and the secreted EspB and EspD translocators. The secretion of T3sNbs
from the cytoplasm of the bacteria to the extracellular medium is indicated. (B) Coomassie staining of TCA-precipitated proteins found in the
extracellular media of cultures of wt EPEC or DescN strains carrying plasmids pSA10, pT3sVamy, or pT3sVgfp, as indicated. Cultures were grown at
37uC in DMEM and induced with 0.1 mM IPTG for 4 h. The protein bands of EspA, EspB, EspD, and that of the Sec-dependent autotransporter EspC,
are labeled. Size in kDa of protein standards for SDS-PAGE are shown on the right. (C) Western blot analysis of the proteins found in extracellular
media (Culture supernantants; lanes 1–6) and cells (bacterial lysates; lanes 7–12) from the same cultures as in (B). WB developed with mAbs anti-E-tag
(top panels) or anti-GroEL (bottom panels) to control the absence of cytoplasmic proteins in the extracellular media. (D) Binding activity of the
secreted sdAbs. ELISA with His-tag purified T3sVgfp (left) and T3sVamy (right), at the indicated concentrations (nM), against their cognate antigens
(GFP or Amy) and BSA (negative control). Bound T3sVHHs developed with anti-E-tag mAb-POD and their Optical Density (O.D.) determined at 490 nm.
doi:10.1371/journal.pone.0015227.g001
E. coli Injection of Active sdAbs into Human Cells
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T3sVHHs were purified (Fig. S5) with standard yields between 0.5–
1 mg/L of culture supernatant. Binding activities of the purified
T3sVHHs were tested by ELISA using antigens Amy, GFP or BSA
(as negative control). Bound T3sVHHs were developed with anti-E-
tag mAb demonstrating the specific antigen-binding activity of the
T3sVHHs over a range of concentrations (Fig. 1D).
Translocation of sdAbs into human cells
We tested whether T3sVHHs can be injected into human cells
with EPEC strain (Fig. 2A). Toward this end, vector pCX340
(Table 2), which encodes the TEM-1 b-lactamase (Bla) reporter
devoid of its natural N-terminal Sec-dependent signal peptide
[26], was used to generate T3s-Bla, T3sVamy-Bla, and T3sVgfp-
Bla fusions (Fig. S6A). Plasmids pT3s-Bla and pCX340 were used
as positive and negative controls of translocation, respectively.
Cultured HeLa cells, infected with wt and DescN EPEC carrying
these Bla-expressing plasmids, were incubated with the nonfluo-
rescent esterified CCF2/AM substrate. Upon passive entry into
the eukaryotic cell, CCF2/AM is transformed by eukaryotic
esterases to the fluorescent substrate of Bla CCF2, which is mostly
contained inside the eukaryotic cell [26]. Injection of Bla into the
cytoplasm of the eukaryotic cells leads to hydrolysis of CCF2
changing its fluorescence emission from 520 nm (green) to 447 nm
(blue), which could be detected under the fluorescence microscope
or quantified in a fluorimeter. Examination by fluorescence
microscopy revealed a clear shift to blue fluorescence of HeLa cells
infected with wt EPEC carrying pT3s-Bla, pT3sVamy-Bla, or
pT3sVgfp-Bla (Fig. 2B). In contrast, green fluorescence was
observed in HeLa cells infected either with wt EPEC/pCX340 or
with any of the DescN strains (Fig. 2B), demonstrating that the
hydrolysis of CCF2 is only due to the Bla translocated into the
cytosol of the HeLa cells. The fluorescence intensity of infected
cells was also quantified in a fluorimeter and is shown as the ratio
between blue emission fluorescence (447 nm) and green emission
fluorescence (520 nm) (Fig. 2C). Expression of Bla fusions in wt
and DescN EPEC was confirmed by WB with anti-Bla antibodies
(Fig. S6B). Thus, these results demonstrate that EPEC carrying a
Figure 2. Translocation of sdAbs into HeLa cells using T3SS of EPEC. (A) Schematic representation of T3SS-complex from EPEC with EspB/D
pore complex assembled in the mammalian cell plasma membrane. Injection of T3sNbs from the cytoplasm of the bacteria to the cytoplasm of the
mammalian cell is shown. (B) Fluorescence microscopy images of cultured HeLa cells infected with EPEC wt (left column) and DescN (right column)
strains, harbouring pCX340, pT3s-Bla, pT3sVamy-Bla or pT3sVgfp-Bla, as indicated, and incubated with CCF2/AM. Hydrolysis of CCF2 by translocated
Bla changes the fluorescence emission of the cytosol of HeLa cells from 520 nm (green) to 447 nm (blue). (C) Quantification of the activity of
translocated Bla by measuring the ratio of fluorescence at 447/520 nm in HeLa cells infected with the indicated bacteria. (D) Western blot of protein
extracts after SLO treatment of HeLa cell cultures infected for the indicated time (min) with wt EPEC and DescN strains harboring pT3sVgfp. Eukaryotic
cytoplasm extracts (top panels) were developed with anti-E-tag mAb to detect T3sVHHs, anti-DnaK mAb to control the absence of bacterial
contamination, and anti-GFP mAb to test the efficacy of SLO pore formation in all samples and as a loading control. SLO-insoluble protein extracts
(bottom panels), corresponding to EPEC bacteria and HeLa cell debris, were developed with anti-E-tag mAb, to show the expression level of T3sNb in
bacteria, and with anti-DnaK mAb to control similar attachment of both strains to HeLa cells. (E) Immunofluorescence microscopy images of Hela cells
infected with EPEC wt and DescN strains to demonstrate similar adhesion and microcolony formation of both strains in HeLa cells. Bacteria are labeled
with anti-O127 serum (red), F-actin labeled with conjugated phalloidin (green), and DNA and cell nuclei labeled with DAPI (blue). Actin accumulation
is only observed underneath wt EPEC.
doi:10.1371/journal.pone.0015227.g002
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human cells.
Next, we investigated whether T3sVHHs could be detected in
the cytoplasm of infected HeLa cells. Toward this end we
employed a fractionation method of the infected cells based on
Streptolysin-O (SLO), a pore-forming cytolysin from Streptococcus
pyogenes that selectively bind to cholesterol groups in the eukaryotic
plasma membrane [32,33]. HeLa cells were infected for 90 or
150 min with EPEC expressing T3sVHHs in the presence of
IPTG, placed on ice and the monolayer washed with PBS.
Following SLO treatment the cytoplasmic content of HeLa cells
was collected (‘‘Eukaryotic cytoplasm’’ extract). Ghost HeLa cells
and bound bacteria were lysed in a SDS-containing buffer (‘‘SLO-
insoluble’’ extract). Protein extracts were subjected to WB
revealing a time-dependent accumulation of T3sVgfp in the
cytoplasm of HeLa cells infected with wt EPEC but not with
EPEC DescN (T3sVHH top panel, Fig. 2D). No sign of bacterial
contamination was detected in the eukaryotic cytoplasmic extracts
using a mAb directed against DnaK (Fig. 2D). Efficiency of the
SLO-treatment in the different samples was controlled by WB
developed with anti-GFP mAb (Fig. 2D). In addition, WB of the
‘‘SLO-insoluble’’ extracts demonstrated similar expression levels of
T3sVgfp in wt EPEC and DescN strains (T3sVHH bottom panel,
Fig. 2D). The comparable signal from the ‘‘SLO-insoluble’’
extracts probed with anti-DnaK indicated similar cell attachment
levels of wt EPEC and DescN (Fig. 2D). This was confirmed by
fluorescence microscopy of the infected cultures (Fig. 2E), in which
microcolonies of wt EPEC and DescN bacteria (red) were stained
adhered to HeLa cells at similar levels, although actin pedestals are
only observed in cells infected by wt EPEC (Fig. 2E, staining of F-
actin in green).
Since wt EPEC also secretes T3sVgfp to the extracellular
medium, we wanted to exclude the possibility that the T3sVgfp
molecules detected in the cytoplasmic extracts entered the cells
indirectly from the extracellular medium through the pores formed
in the plasma membrane by the EspBD translocation pore or
during the SLO-treatment (despite removal of the extracellular
medium before addition of SLO). For this, HeLa cells were
infected with wt EPEC harboring empty pSA10 (expressing a
functional T3SS but not T3sVgfp) or EPEC DescN/pT3sVgfp
(lacking a functional T3SS and thus unable to inject T3sVgfp).
After 120 min of infection, the culture media was replaced by
conditional, bacteria-free, medium obtained from an induced wt
EPEC/pT3sVgfp culture (containing secreted T3sVgfp). After a
further 30 min incubation, infected cells were fractionated with
SLO into ‘‘eukaryotic cytoplasm’’ and ‘‘SLO-insoluble’’ extracts,
as above. WB showed that T3sVgfp was not found in the
‘‘eukaryotic cytoplasm’’ (Fig. S7), hence ruling out the possibility
that T3sVgfp molecules were entering HeLa cells from the
extracellular medium. Taken together, the experiments with Bla
reporter and biochemical fractions demonstrated that wt EPEC
are able to directly inject T3sVHHs into human cells.
We also investigated whether the presence of their cognate
antigen influence the stability of T3sVHHs. Toward this end HeLa
cells, transfected with pEGFP-N1 or with the empty vector
pCS2+MT (Table 2), were infected with wt EPEC and EPEC
DescN harboring pT3sVgfp. ‘‘Eukaryotic cytoplasm’’ and ‘‘SLO-
insoluble’’ extracts were analyzed by WB revealing that the
amount of T3sVgfp found in the cytoplasm of HeLa cells was ,3-
fold higher when GFP was expressed (Fig. 3A, T3sVHH panel).
Detection of the cytoplasmic enzyme glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a loading control of the
‘‘eukaryotic cytoplasm’’ extracts (Fig. 3A, GAPDH panel). WB
with anti-DnaK demonstrated the absence of bacterial contami-
nation in the ‘‘eukaryotic cytoplasm’’ extracts and similar signals in
the ‘‘SLO-insoluble’’ extracts (Fig. 3A, DnaK panels). Therefore,
higher levels of injected T3sVHHs are found when HeLa cells
express the relevant antigen. We estimated that after 150 min
infection in the presence of IPTG, an average of ,7610
5
molecules of T3sVgfp per cell are found in pEGFPN1-transfected
cells. This estimation was done by densitometry of the WB signals
of T3sVgfp in ‘‘eukaryotic cytoplasm’’ extracts from three
independent infections with the signals generated with known
protein concentrations of purified T3sVgfp used as standard curve
(Fig. S8).
Antigen binding activity of injected sdAbs
To investigate formation of intracellular antigen-VHH complex-
es, ‘‘eukaryotic cytoplasm’’ extracts from pEGFP-N1-transfected
cells, infected with wt EPEC carrying pT3sVgfp or pT3sVamy,
were immunoprecipitated (IP) with anti-E-tag mAb bound to
protein G-beads. WB of the input extracts and IP proteins (Fig. 3B)
revealed that GFP was specifically co-IP from the cytoplasmic
extracts of cells infected with EPEC/pT3sVgfp demonstrating the
formation of intracellular GFP-T3sVgfp complexes. Since
T3sVamy does not accumulate at detectable levels in the
cytoplasm of HeLa cells (likely caused by the absence of its
antigen in the cytoplasm; see Discussion), purified T3sVamy was
added to the input extract of cells infected with EPEC/pT3sVamy
to provide a control of the specific co-IP of GFP with T3sVgfp
(Fig. 3B). Similar amounts of GFP and GAPDH proteins were
detected in the input extracts (Fig. 3B). These data provide direct
evidence that the injected T3sVHHs have the capacity to bind their
specific antigen in the cytoplasm of human cells.
Translocation of sdAbs by attenuated EPEC
The EPEC wt strain is a pathogen causing strong cytopathic
effects due to the injection of its natural repertoire of T3 effectors
[14,18]. Therefore most biotechnological applications will require
using attenuated strains deficient in the major or all of the T3
effectors. To obtain a proof-of-principle of the injection of VHHs
with attenuated bacteria, we employed quadruple (‘‘quad’’)
mutant strain of EPEC that assembles functional injectisomes
but carries four deletions in genes encoding the adhesin intimin
and the effectors Tir, EspF and Map [34]. Bla translocation assays
in HeLa cells infected with the ‘‘quad’’ mutant or with EPEC
DescN (as a control) demonstrated the injection of T3s-Bla,
T3sVamy-Bla and T3sVgfp-Bla by the ‘‘quad’’ mutant strain
(Fig. 4A). The emission ratio at 447/550 nm obtained with the
‘‘quad’’ mutant were ,60% those reached with wt EPEC
(compare Fig. 2C and Fig.4A) suggesting a lower infection efficacy
with the attenuated mutant. T3sVgfp was also detected in the
cytoplasmic extracts of HeLa cells transfected with pEGFPN1 and
infected with ‘‘quad’’ mutant’’ (Fig. 4B). Infection with wt EPEC
and DescN bacteria, both carrying pT3sVgfp, were used as positive
and negative controls, respectively. The level of translocated
T3sVgfp by the ‘‘quad mutant’’ strain was found to be ,60% that
reached by the wt EPEC strain (Fig 4B, T3sVHH top panel).
Absence of bacterial contamination in the cytoplasmic extracts was
confirmed with anti-DnaK and detection of GAPDH and GFP
was used as a control of gel loading and of the efficacy of the SLO-
treatment. ‘‘SLO-insoluble’’ extracts showed similar levels of
T3sVgfp and DnaK in infections with EPEC wt and ‘‘quad’’
strains (Fig. 4B). Fluorescence microscopy of infected cells showed
microcolonies of the ‘‘quad’’ strain on the surface of HeLa cells
and the absence of F-actin pedestals (Fig. 4C). Altogether these
data demonstrate an attenuated E. coli strain with a functional
T3SS is capable of translocation of T3sVHHs into HeLa cells.
E. coli Injection of Active sdAbs into Human Cells
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15227Figure 4. Injection of sdAbs by attenuated bacterial strain. (A) Quantification of the Bla activity by measuring the ratio of fluorescence at 447/
520 nm in HeLa cells infected with quad mutant and DescN strains, carrying the indicated plasmids. (B) Western blot of ‘‘eukaryotic cytoplasm’’ (top
panels) and ‘‘SLO-insoluble’’ (bottom panels) extracts from infected HeLa cell cultures with wt EPEC, quad mutant, and DescN strains harboring
pT3sVgfp. WB developed as in Figs 2 and 3. (C) Immunofluorescence microscopy images of Hela cells infected with the quad mutant and DescN
strains, to demonstrate the absence of actin pedestals and similar adhesion and microcolony formation by the attenuated quad mutant. Bacteria are
labeled with anti-O127 serum (red), F-actin labeled with conjugated phalloidin (green), and DNA and cell nuclei labeled with DAPI (blue).
doi:10.1371/journal.pone.0015227.g004
Figure 3. Antigen binding recognition by translocated sdAbs. (A) Antigen expression (GFP) increases the level of T3sVgfp detected in the
cytoplasm of HeLa cells. Western blot of ‘‘eukaryotic cytoplasm’’ (top panels) and ‘‘SLO-insoluble’’ (bottom panels) protein extracts from infected
HeLa cell cultures transfected with the indicated plasmids: pEGFPN1 (GFP) or control pCS2+MT (mock). Infections were carried out for 150 min with
EPEC wt and DescN strains harboring pT3sVgfp. The level of T3sVgfp in the cytoplasmic extracts of HeLa cells was developed with anti-E-tag mAb
(T3sVHH top panel). Absence of bacterial contamination in eukaryotic cytoplasm protein extracts was controlled with anti-DnaK mAb (DnaK top
panel). Transfection and expression of GFP was controlled with and anti-GFP mAb (GFP panel). Levels of human cytoplasmic GAPDH were determined
with anti-GAPDH mAb to control equal SLO pore formation in all samples and as a loading control. SLO-insoluble protein extracts (bottom panels)
were developed with anti-E-tag mAb to show the level of T3sVgfp in bacteria and with anti-DnaK mAb to control bacterial attachment. (B)
Immunoprecipitation of T3sVgfp:GFP complexes from the cytoplasm of infected HeLa cells. Western blot of input eukaryotic cytoplasm protein
extracts and immunoprecipitated proteins with anti-E-tag mAb bound to protein G-Sepharose resin. Input extracts were obtained by SLO treatment
from pEGFP-N1-transfected HeLa cell cultures infected with wt EPEC strain carrying pT3sVgfp or pT3sVamy. Purified T3sVamy was added to one
aliquot of input extract from cells infected with EPEC/pT3sVamy (lane 3) to reach a level similar to the translocated T3sVgfp (lane 1). Input extracts
were developed with anti-E-tag, anti-GFP, and anti-GAPDH mAbs (top panels). Immunoprecipitated (IP) proteins were developed with anti-E-tag and
anti-GFP mAbs (bottom panels).
doi:10.1371/journal.pone.0015227.g003
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Expression of Ab fragments in the cytoplasm of human cells
allows targeting of intracellular proteins that participate in disease
and infection processes [7]. In this work we have shown that non-
invasive E. coli bacteria carrying a functional T3SS are able to
secrete and translocate to the cytoplasm of human cells sdAb
fragments with full capacity to bind their cognate antigens. Single-
domain VHHs appeared specially suited for this application given
their potential as enzyme inhibitors, monomeric nature, stability,
and size (2–3 nm diameter) [5] that fit in the protein channels of
T3 needles and EspA filament [19,35]. We have shown that T3-
secreted VHHs present in the extracellular medium do not enter in
the cytoplasm of HeLa cells via EspBD pores, and that
translocation only occurs directly from bacteria to the mammalian
cell. In addition, we obtained evidence of the formation of antigen-
VHH complexes in the cytoplasm of the infected cells and
quantified that ,7610
5 VHH molecules accumulated per cell in
the presence of antigen. Interestingly, we found that expression of
the antigen in the cytoplasm of the mammalian cell increases the
level of VHHs in the cytoplasm, which suggests that formation of
antigen-VHH complex could stabilize the intracellular VHH.
Although the actual reason of this stabilization is unclear, it is
possible that the higher molecular weight of the antigen-VHH
complex might reduce its susceptibility to proteolyic degradation in
vivo. In this regard, detection of translocated T3sVHH-Bla in cells
that do not express their cognate antigens could also be explained
by their higher molecular weight of these fusions.
To establish this proof-of-principle we took advantage of non-
invasive intestinal pathogenic E. coli strains that harbor a T3SS,
such as EPEC and EHEC [12,13]. Although in vivo infection by
these strains is restricted to humans and certain animals (e.g.
cattle), in vitro they can infect many mammalian cell lines from
distinct cell types and species, including human and murine
epithelial cells, fibroblasts, and macrophages among others [36–
38]. Interestingly, the mouse pathogen Citrobacter rodentium also
carries a LEE pathogenicity island encoding a T3SS almost
identical to that found in EPEC and EHEC strains [39].
Applications of intrabody delivery by bacterial injection require
the use non-pathogenic bacterial strains. In this study we
employed an attenuated strain lacking the adhesin Intimin and
three major T3-effectors (EspF, Map, Tir) of EPEC. In the
absence of intimin and Tir EPEC looses its intimate adhesion and
actin pedestal formation capabilities, while the lack of EspF and
Map diminishes major cytopathic effects due to disruption of the
mitochondria and activation of Rho GTPases [14,34]. A study
with human volunteers who ingested an EPEC null mutant in the
intimin gene (eae) demonstrated a strong attenuation of this strain
[40]. The EPEC strain E2348/69 used in this study encodes 21
effectors of the T3SS [12]. Accordingly, it would be possible to
engineer an attenuated E. coli strain lacking all these effectors
following a genome minimization approach [41]. Such bacterial
strain will be extremely useful for antibody injection into
mammalian cells. Another appealing strategy for bacterial
injection of sdAbs is the use of commensal E. coli strains endowed
with a functional T3SS. It has been reported that E. coli K-12
strain carrying the complete LEE from EPEC on a cosmid is able
to induce actin polymerization in human cells in vitro [42].
However, the LEE is expressed weakly in E. coli K-12 [43] and,
therefore, additional engineering is needed for efficient injection
from E. coli K-12.
The use of extracellular bacteria with a T3SS as vectors for
delivery of proteins (including intrabodies) into mammalian cells
differs from other approaches that need the transfer of the protein-
encoding gene by viral infection or transfection [8]. Invasive E. coli
expressing the Invasin (Inv) from Yersinia and the Listeriolysin O
(LLO) from Listeria have been employed previously to deliver
proteins, DNA, and interfering shRNA into mammalian cells [11].
Upon cell invasion, invasive E. coli cells (Inv+ LLO+) are lysed in
the phagosomes releasing their total cellular content. In contrast to
this situation, non-invasive E. coli cells carrying a T3SS remain
extracellular and could inject specifically the desired sdAb. In
addition, extracellular E. coli bacteria are more sensitive to
antibiotic treatment (e.g. gentamycin) facilitating their elimination
from in vitro cultures as well as from whole animals in vivo.
The use of live bacteria has a great potential for delivery of
therapeutic proteins in vivo, in specific organs or tissues of the
animal, where they can produce a continuous supply of the
polypeptide. For instance, probiotic strains of lactic acid bacteria
have been used in vivo for the extracellular secretion of cytokines,
enzymes, antibody fragments, etc. against infectious and inflam-
matory diseases [44–46]. Also mucosal and systemic infections
with live attenuated invasive bacterial strains (e.g. Salmonella,
Listeria) have been employed for intracellular delivery of antigens
for vaccination and cytotoxins for tumor therapy [47–54].
Interestingly, probiotic E. coli strains are currently used as
therapeutic agents in humans. For instance, colonization of the
gastrointestinal tract by E. coli Nissle 1917 [55] is used to treat
some inflammatory bowel diseases such as Crohn’s disease
[56,57]. In addition, deliberate colonization of the urinary bladder
with probiotic E. coli strain ABU83972, isolated from an
asymptomatic bacteriuria patient [58], is being used to treat
recurrent urinary tract infections by uropathogenic E. coli strains
[59,60]. Therefore, an attractive possibility is to engineer probiotic
E. coli strains to carry a functional T3SS to deliver intracellularly
therapeutic sdAbs targeting proteins involved in diseases such as
inflammation and cancer in the gastrointestinal and urinary tracts.
Systemic infections to treat other organs and solid tumors are not
excluded [61,62]. Importantly, sdAbs interfering the function of
relevant intracellular targets involved in cell proliferation (e.g.
Ras), apoptosis (e.g. Caspase-3), cell migration (e.g. Gelsolin), and
HIV-replication proteins (e.g. Rev) have already been selected
[63–66]. The levels of intracellular sdAbs reported here with the E.
coli T3SS (10
5–10
6 molecules per cell) seem appropriated to
modulate the activity of regulatory and cell-signaling proteins,
which often have intracellular levels below 10
6 molecules per cell
[67,68] and, in addition, could trigger a downstream signaling
cascade that would amplify the initial effect of the intrabody.
In conclusion, we believe that injection of sdAbs into
mammalian cells using non-pathogenic bacterial strains carrying
a T3SS is a promising technology for in vitro and in vivo intrabody
applications that target host cell functions and signaling pathways.
Materials and Methods
Bacterial strains, growth, induction and infection
conditions
Escherichia coli strains used in this work are listed in Table 1
[12,13,34,37,69,70]. Bacteria were grown at 37uC in Luria-
Bertani (LB) agar plates, in liquid LB medium or in Dubelcco’s
modified Eagle’s medium (DMEM), as indicated. Media were
supplemented with appropriated antibiotics for selection. Antibi-
otics were used at the following concentrations: Ampicillin (Ap)
150 mg/ml; Chloramphenicol (Cm) 30 mg/ml; Kanamycin (Km)
40 mg/ml; Tetracycline (Tc) 10 mg/ml. For secretion into the
extracellular media of sdAbs, 5 ml cultures were grown overnight
in LB at 37uC under static conditions. Next day, these cultures
were used to inoculate 15 ml of DMEM (initial OD600,0.05) in a
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at 37uC with shaking until OD600,0.4. At this point, 0.1 mM
isopropyl-1-thio-b-D-galactoside (IPTG) was added for 4 h. For
infection experiments, overnight LB cultures (as above) were used
to inoculate 15 ml of DMEM (initial OD600,0.1) and the cultures
were incubated under static conditions at 37uC with 5% CO2 for
2 h, as a pre-activation step. Bacteria from these cultures were
used for infection of HeLa cell cultures (,10
5 cells/well in 24-well
tissue culture plates; Falcon) at a multiplicity of infection (MOI)
300:1 (bacterial CFUs: HeLa cells) and 0.1 mM IPTG was added.
Infection continued at 37uC with 5% CO2 for the indicated time
(90–150 min) and were stopped on ice.
Plasmids and DNA constructs
Plasmids employed in this study are summarized in Table 2.
Standard methods of DNA manipulation were used [71]. All DNA
constructs were sequenced using an automated DNA sequencer
(Perkin Elmer). Oligonucleotides were synthesized by Sigma
Genosys (Table 3). Plasmid pSA10 is a vector that contains lacI
q
repressor and a multiple cloning site under the control of Ptac
promoter [72]. Plasmid pT3sVamy contains a DNA fragment of
549 bp, cloned at the EcoRI site of pSA10 under the Ptac
promoter, which encodes the VHH anti-amylase (Vamy) fused to
the T3-signal EspF20 at its 59-end and a six-histidine (His) tag and
the 12-amino acid epitope E-tag (GAPVPYPDPLEP) at its 39-end.
This DNA fragment was obtained by EcoRI digestion of a 560 bp
DNA product generated by homology-driven PCR, fusing two
PCR subfragments with a final amplification of the fused product
with oligonucleotides R1-Xb-SD-espF y RI-stop-E (Table 3).
Subfragment 1 (119 bp), containing EspF20 signal, was amplified
from genomic DNA from EDL933stx with primers R1-Xb-SD-
espF and SfiI-espF. Subfragment 2 (517 bp), corresponding to
Vamy with His and E-tag epitopes, was amplified using plasmid
pEHLYA4SDVamy as a template and oligonucleotides SfiIVamy
and RI-stop-E as primers. Plasmid pEHLYA4SDVamy is a
derivative of pEHLYA2SDVamy [28] with the His and the E-tag
epitope at the 39end of Vamy. Plasmid pT3sVgfp was obtained by
SfiI and NotI digestion of pT3sVamy, substituting Vamy coding
sequence by Vgfp. The DNA encoding Vgfp was obtained by
PCR using plasmid pcAbGFP4 [73] as template and oligonucle-
otides Vhh-sfiI2 and Vhh-NotI2 as primers. The amplified
fragment was digested with SfiI and NotI and the resulting
358 bp DNA molecule was cloned in the backbone of vector
pT3sVamy (,4.3 kb) digested with the same enzymes. Plasmid
pDsVgfp was constructed by amplication of a DNA segment,
encoding Vgfp-His-E-tag devoid of the T3-signal, from pT3sVgfp
template with oligonucleotides Dsign-EcoRI and RI-stop-E. The
,0.5 kb PCR product was digested EcoRI and inserted in the
same site of vector pSA10 under the control of Ptac promoter.
Plasmids pT3s-Bla and pT3sVamy-Bla are derivatives of
pCX340 [26], a vector employed to make fusions with the TEM
b-lactamase lacking its Sec-dependent-signal peptide (‘blaM). To
construct pT3s-Bla, first an 83 bp DNA segment encoding the T3-
signal of EspF was amplified from genomic DNA from EDL933stx
with the oligonucleotides NdeI-espF and EcoRI-espF. Next, this
DNA segment was fused, by homology-driven PCR, with a 1.2 kb
DNA fragment encoding (‘blaM), that had been amplified from
pCX340 with oligonucleotides EcoRI-TEM and BamHI-tetra.
The resulting 1.3 kb fragment, amplified with oligonucleotides
NdeI-espF and BamHI-tetra, was digested with NdeI and BamHI
and ligated with backbone fragment of pCX340 digested with the
same enzymes. To construct pT3sVamy-Bla, a DNA fragment
encoding T3sVamy was amplified from plasmid pT3sVamy with
oligonucleotides NdeI-espFVamy and EcoRIVamy-espF, digested
with NdeI and EcoRI and ligated in the same sites of pCX340.
In vitro cell culture and plasmid transfection
The human epithelial cell line HeLa clone HtTA1 was grown as
monolayer in DMEM, supplemented with 10% fetal bovine serum
(FBS) and 2 mM glutamine, at 37uC with 5% CO2. For
transfection, HeLa cells were seed in tissue 24-well culture plates
(,10
5 cells/well), grown for 20 h at 37uC with 5% CO2. Plasmid
pEGFPN1 (Clontech) or pCS2+MT [74] was added (0.6 mg
DNA/well) to the cultures in calcium phosphate [75]. After 22 h
incubation, the medium was removed, wells were washed three
times with PBS, filled with 1 ml of complete medium and
incubated for 1 h at 37uC with 5% CO2. This medium was
replaced by serum-free medium before cell cultures were infected
as described above.
SDS-PAGE and Western blot analysis
Sodium Dodecy Sulfate–Polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blot was performed following standard
methods [71] using the Miniprotean III system (Bio-Rad). Proteins
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Coomassie Blue R-250 (Bio-Rad) or transferred to polyvinylidene
difluoride membrane (PVDF, Immobilon-P, Millipore) as de-
scribed previously [76]. Antibodies employed for Western blot
were: anti-E-tag mAb conjugated to peroxidase (POD) (1:5000;
GE Amersham Biosciences); anti-E-tag mAb (Phadia; 0.5 mg/ml),
anti-GroEL mAb-POD (1:5000; Sigma); anti-b-lactamase mAb
(1:1000; QED Bioscience); anti-GFP mAb (1:1000; Roche); anti-
GAPDH (1:2000; Santa Cruz Biotechnology); anti-DnaK (1:5000;
Stressgen). Unconjugated mAbs were detected with anti-mouse
IgG-POD (1:5000; Sigma) as secondary antibody. Membranes
were developed by chemiluminiscence using Immun-Star Wes-
ternC kit (Bio-Rad) and exposed to X-ray films (Konica) and to a
ChemiDoc XRS+ system for quantification (Bio-Rad).
Analysis of secreted and cellular proteins in E. coli strains
Whole-cell protein extracts from induced E. coli cultures were
obtained from cells harvested by centrifugation (30006g, 5 min)
from 1 ml aliquot of liquid cultures (OD600,1.2), resuspended in
100 ml of phosphate-buffered saline (PBS), and mixed with the
same volume of 2X SDS-PAGE sample buffer. Samples were
boiled for 10 min, briefly sonicated (5 sec; Labsonic B Braun), and
centrifuged (140006g, 5 min) to remove insoluble material before
loading on SDS-PAGE. For analysis of proteins secreted in the
culture medium, culture supernatants obtained after centrifugation
(30006g, 15 min) were filtered utilizing a 0.22-mm sterile low-
protein binding PVDF filter unit (Millex GV, Millipore) and the
serine-protease inhibitor phenyl-methyl-sulphonyl-fluoride (PMSF)
was added to 1 mM final concentration. The proteins in the
filtered-culture supernatants were mixed with 1/5th of the volume
of SDS-PAGE sample buffer (5X) for WB or were precipitated
with trichloroacetic acid (TCA 20% w/v; Merck) for Coomassie
staining. After centrifugation (140006g, 15 min), TCA-precipitat-
ed protein pellets were rinsed with cold acetone (220uC) and
resuspended in SDS-PAGE sample buffer (1/10th of the
precipitated volume). Purification of His-tagged T3-secreted sdAbs
with Talon resin (Clontech) is described below. To test the
solubility of the T3-secreted sdAbs, the filtered-culture super-
nantants (see above) were centrifuged at 100.0006g in a Beckman
TL-100 ultracentrifuge for 1 h at 4uC. The supernatant (Soluble)
and the pellet (insoluble) fractions obtained after this centrifugation
were adjusted to the same final volume in SDS-PAGE sample
buffer, boiled and analyzed by WB.
Purification of T3-secreted sdAbs
Cultures of E. coli EPEC with the indicated plasmids
(pT3sVamy or pT3sVgfp) were grown at 37uC with shaking in
200 ml of DMEM with ampicillin (using a capped bottle). IPTG
was added at 0.1 mM final concentration when the OD600
reached ,0.4 and incubation continued for 4 h. Culture
supernatants were filtered and PMSF was added as described
above. Next, supernatants were equilibrated to PBS 1X and
incubated overnight at 4uC with 2 ml of Cobalt-containing
chromatography resin (Talon, Clontech) for binding of His-tagged
sdAbs. Resin was packed in a column, washed 4 times with 10 ml
of PBS containing 5 mM imidazole, and eluted in 1 ml aliquots
with PBS containing 100 mM imidazole. Eluted fractions were
stored at 4uC.
Enzyme-linked immunosorbent assays (ELISA)
ELISA conditions were based on those described previously
[76]. Briefly, 96-well immunoplates (Maxisorp, Nunc) were coated
for 2 h at room temperature with purified antigens (10 mg/ml) in
PBS. Antigens employed: alpha-amylase (Amy; Sigma), the green
fluorescent protein (GFP; Upstate), bovine serum albumin (BSA,
Roche). Plates were washed with PBS and blocked in PBS buffer
containing 3% (w/v) non-fat milk, before incubation with purified
T3-secreted sdAbs or filtered-culture supernatants obtained after
IPTG induction (at the indicated concentration or dilution in the
same buffer). After PBS-wash, bound E-tagged sdAbs were
revealed with anti-E-tag mAb-POD (1:2000) and developed with
o-phenylenediamine (OPD, Sigma) and H2O2 (Sigma). The OD
at 490 nm of the plates was determined in a microplate reader
(Bio-Rad).
b-lactamase translocation assay
We followed the method described by [26]. Briefly, the
indicated bacterial strains were used to infect HeLa cells grown
in vitro in 8-well Falcon culture slides (Beckton Dickinson), IPTG
was added for induction and incubation continued for 90 min.
The medium was removed and cells were washed three times with
Hank’s balance salt solution (HBSS). Next, 200 ml of HBSS and
40 ml of the b-lactamase substrate CCF2/AM mix (K1024,
Invitrogen) were added. Cells were incubated for additional
90 min at room temperature in the dark, washed three times with
HBSS and analyzed by fluorescence microscopy (Nikon Eclipse
E600, excitation UV light 330–380 nm). For quantitative analysis
of Bla translocation, HeLa cells were seeded in a 96-well opaque
plate (Nunc) at aprox. 85% confluence (,2610
4 cells/well). After
16 h incubation at 37uC with 5% CO2, infection were done with
pre-activated EPEC strains in serum-free DMEM and the cultures
were further incubated for 30 min before addition of IPTG, and
60 min after this addition. Infections were washed three times with
HBSS, and 200 ml/well of HBSS were added plus 20 ml of CCF2/
AM substrate mix. Samples were incubated for 90 min in the dark,
washed three times with HBSS and finally 100 ml/well of HBSS
were added. Plates were read in a FLUOstar Optima Microplate
Fluorometer with a filter set 450/520 nm.
Streptolysin-O (SLO) fractionation of infected cell cultures
Conditions of SLO treatment were based on those described by
[77] with some modifications. Briefly, 24-well plates containing
infected HeLa cell cultures (as described above) were placed on ice
and washed three times with 1 ml/well of freshly prepared cold
SLO-buffer (150 mM sucrose, 25 mM Hepes pH 7.4, 150 mM
K-acetate, 2.5 mM MgCl2, 4 mM EGTA, 2 mM DTT). Next,
175 ml/well of SLO-buffer containing 10 mg/ml of Streptolysin O
(purchase from Prof. Sucharit Bhakdi’s laboratory, Institute of
Medical Microbiology and Hygiene, Hochhaus am Augustusplatz,
Mainz, Germany) were added followed by 15 min of incubation
on ice to allow binding of SLO to cells. After this incubation,
unbound SLO was removed by washing three times with 1 ml/
well of cold SLO buffer and 175 ml/well of this buffer was added.
Plates were incubated at 37uC for 15 min for SLO-pore formation
to allow release of the cytosolic content of HeLa cells (which was
confirmed by observation in an inverted light microscope; Carl
Zeiss). Extracellular media containing released cytoplasmic
proteins were collected from plates. Protease inhibitors were
added (Complete EDTA-free Protease Inhibitors Cocktail, Roche)
to these extracts and centrifuged at 45006g (15 min, 4uC) in order
to eliminate any bacteria and cells detached from plates. This
supernatant was collected and centrifuged at 160006g (15 min,
4uC). The final resulting supernatant was referred to as
‘‘eukaryotic cytoplasm’’ protein extract. Eukaryotic cells debris
and bacteria that remained attached to plates after SLO treatment
were collected in 175 ml/well of a SDS-PAGE sample buffer (1x)
and this extract was referred to as ‘‘SLO-insoluble’’ protein
extract.
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Eukaryotic cytoplasm protein extracts (350 ml obtained as
described above from two infected tissue culture wells) were
incubated with 40 ml of anti-E-tag mAb bound to protein G-
Sepharose resin. Anti-E-tag mAb (1 mg, Phadia) was previously
crosslinked to protein G-Sepharose resin (1 ml, Sigma) with
dimethyl pimelimidate dihydrochloride (DMP; Sigma). After 16 h
incubation at 4uC in an orbital shaker, the resin was collected by
centrifugation (8006g, 1 min) and washed three times with 1.5 ml
of 200 mM sodium phosphate buffer (pH 8.2). Bound proteins
were eluted from resin by incubation with 60 ml of 0.1 M glycine
pH 2.8 (10 min at room temperature) followed by centrifugation
(8006g, 1 min). Supernatants were collected and 30 mlo f
200 mM sodium phosphate buffer (pH 8.2) was added for pH
neutralization, referred to as immunoprecipitated (IP) proteins.
Routinely, 12 ml of these IP proteins were mixed with 3 mlo f5 X
SDS-PAGE sample buffer, boiled and gel-loaded for Western blot
analysis.
Immunofluorescence microscopy
Infected HeLa cell cultures, grown on coverslips in 24-well
plates, were washed three times with 1 ml/well of PBS, fixed with
3% (w/v) paraformaldehyde (in PBS) for 20 min at room
temperature, and washed again with PBS three times. Cells were
permeabilized by incubation with PBS containing 0.1% (v/v) of
Triton X-100 (Sigma) for 5 min. To label EPEC, a rabbit
polyclonal anti-O127 serum was diluted 1:200 in PBS with 10%
donkey serum (Jackson Immunoresearch) and incubated 1 h at
room temperature. Coverslips were washed three times with PBS
and goat anti-rabbit IgG-Texas Red conjugated secondary
antibody (1:500 in PBS with 10% donkey serum; Molecular
Probes) was added along with Oregon-Green conjugated phalloi-
din (1:100; Invitrogen) and DAPI (1:1000; Sigma) to label F-actin
and DNA, respectively. Coverslips were washed three times with
PBS after incubation and 4 ml of mounting medium (DAKO) was
added. Coverslips were analyzed by conventional epifluorescence
microscopy using a Zeiss Axio imager microscope.
Supporting Information
Figure S1 Scheme of plasmid vectors used for expres-
sion of T3sVHH fusions. The sequence encoding the first 20
amino acids of EspF effector (T3s) is fused to the corresponding
VHH (Vamy or Vgfp in pT3sVamy or pT3sVgfp, respectively).
Epitope tags (His and E-tag) at the C-termini of fusions and unique
restriction sites SfiI, NcoI and NotI flanking VHH domain are
indicated. Gene constructs are under the control of the IPTG-
inducible Ptac promoter. The presence of lacI
q repressor,
transcriptional terminators (T1,T2) from 5S ribosomal RNA gene,
ampicillin-resistance (amp
r) gene, and origin of replication (ori) are
also shown.
(TIF)
Figure S2 Secretion of T3sVHHs by EHEC. (a) Proteins
found in extracellular media (Culture supernantants; lanes 1–6)
and cells (Bacterial lysates; lanes 7–12) from cultures of wild type
EHEC or DescN mutant strains carrying plasmids pSA10,
pT3sVamy, or pT3sVgfp, as indicated, analyzed by Western blot
with mAb anti-Etag (top panels), to detect T3sVHH fusions, or with
anti-GroEL (bottom panels) to control the absence of bacterial
lysis. Cultures were grown at 37uC in DMEM and induced with
0.1 mM IPTG for 4 h. (b) SDS-PAGE and Coomassie staining of
proteins found in the extracellular media of cultures of EHEC and
DescN mutant strains carrying the indicated plasmids and induced
as in (a). The protein bands of T3sVHH fusions, T3SS- effectors
EspA, EspB, EspD, and that of the Sec-dependent autotransporter
EspP, are labelled. Size in kDa of protein standards for SDS-
PAGE is shown on the left.
(TIF)
Figure S3 Requirement of the T3-signal for secretion of
VHHs. Western blot with anti-E-tag mAb-POD of proteins found
in extracellular media (Culture supernatants) and cells (Bacterial
lysates) from cultures of wild type EPEC (top panels) and EHEC
(bottom panels) carrying plasmids pT3sVgfp or pDsVgfp (lacking
the T3-signal) as indicated. Cultures were grown at 37uCi n
DMEM and induced with 0.1 mM IPTG for 4 h.
(TIF)
Figure S4 Solubility of the T3-secreted VHHs. Extracellular
media from induced cultures of EPEC carrying plasmids
pT3sVgfp or pT3sVamy, as indicated, were ultracentrifuged
(100.0006g, 1 h) and proteins present in the resulting supernatants
(S) and pellet (P) fractions were analyzed by Western blot with
anti-E-tag mAb-POD.
(TIF)
Figure S5 Purified T3sVHHs from culture supernatants.
Coomassie stained SDS-polyacrylamide gel of metal affinity
purified His-tagged T3sVgfp and T3sVamy from extracellular
media of EPEC strains harbouring pT3sVgfp or pT3sVamy. Size
in kDa of protein standards for SDS-PAGE is shown on the left.
(TIF)
Figure S6 Expression of b-lactamase fusions in EPEC.
A) Scheme of b-lactamase (Bla) gene fusions in plasmids pCX340,
pT3s-Bla, pT3sVgfp-Bla and pT3sVamy-Bla. The position of Ptac
promoter, T3 signal and VHH sequence, are indicated. B) Western
blot developed with anti-b-lactamase mAb of whole cells protein
extracts from induced EPEC wild type and DescN strains carrying
the indicated Bla plasmid. Size in kDa of protein standards for
SDS-PAGE is shown on the right.
(TIF)
Figure S7 T3sVHHs do not enter into HeLa cells from
extracellular media. Western blot of ‘‘eukaryotic cytoplasm’’
(top panels) and ‘‘SLO-insoluble’’ (bottom panels) protein extracts
from infected HeLa cell cultures with EPEC wt/pSA10 and EPEC
DescN/pT3sVgfp in which their extracellular media were replaced
by medium containing T3sVgfp from induced EPEC wt/
pT3sVgfp. Western blot of ‘‘eukaryotic cytoplasm’’ extracts are
developed with anti-E-tag to detect T3sVHH, anti-DnaK to control
the absence of bacterial contamination and anti-GFP mAb to test
the efficacy of SLO pore formation. Western blot of ‘‘SLO
insoluble’’ extracts are developed with anti-E-tag to show the
expression of T3sVHH in bacteria and anti-DnaK mAb to control
attachment of both strains to HeLa cells.
(TIF)
Figure S8 Quantification of T3sVHHs molecules inject-
ed. ‘‘Eukaryotic cytoplasm’’ protein extracts of pEGFPN1-
transfected HeLa cells, infected with EPEC wt/pT3sVgfp, were
analyzed by Western blot and the chemiluminiscence intensity of
the protein band corresponding to T3sVHH determined by
densitometry in a Chemi-Doc (Bio-Rad). The average intensity
signal of T3sVHH corresponding to ca. 2300 HeLa cells from three
independent infection experiments (closed circle) is interpolated to
a stardard curve generated with the intesity of protein bands from
samples of purified T3sVgfp of known concentration (open circles).
(TIF)
E. coli Injection of Active sdAbs into Human Cells
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e15227Acknowledgments
We would like to thank Prof. Brendan Kenny (University of Newcastle,
UK) for his kind gift of the quad mutant strain, and Prof. Jorge Blanco
(Universidad de Santiago de Compostela, Spain) for his kind gift of anti-
O127 serum. We thank Dr. Junkal Garmendia (IDAB, CSIC) and Dr.
Gustavo Bodelo ´n (CNB, CSIC) for helpful comments and discussions. The
help of Drs. Cristina Risco and Alberto Fraile (CNB, CSIC) for establishing
the SLO treatment conditions is greatly appreciated.
Author Contributions
Conceived and designed the experiments: ABT LAF. Performed the
experiments: ABT. Analyzed the data: ABT SM GF LAF. Contributed
reagents/materials/analysis tools: ABT SM GF LAF. Wrote the paper:
ABT LAF.
References
1. Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody
fragments. Nat Biotech 27: 331–337.
2. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, et al. (2009) Single
domain antibodies: promising experimental and therapeutic tools in infection
and immunity. Med Microbiol Immunol 198: 157–174.
3. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of
single domains. Nat Biotechnol 23: 1126–1136.
4. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain
antibodies: proteins for therapy. Trends Biotechnol 21: 484–490.
5. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, et al.
(2009) Camelid immunoglobulins and nanobody technology. Vet Immunol
Immunopathol 128: 178–183.
6. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat
Biotechnol 23: 1147–1157.
7. Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and
their therapeutic potential. Handb Exp Pharmacol. pp 343–373.
8. Kontermann RE (2004) Intrabodies as therapeutic agents. Methods 34:
163–170.
9. Ferna ´ndez LA (2004) Prokaryotic expression of antibodies and affibodies. Curr
Opin Biotechnol 15: 364–373.
10. Mazor Y, Van Blarcom T, Mabry R, Iverson BL, Georgiou G (2007) Isolation of
engineered, full-length antibodies from libraries expressed in Escherichia coli.N a t
Biotechnol 25: 563–565.
11. Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, et al. (2004)
Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther
11: 1224–1233.
12. Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, et al. (2009) Complete
Genome Sequence and Comparative Genome Analysis of Enteropathogenic
Escherichia coli O127:H6 Strain E2348/69. J Bacteriol 191: 347–354.
13. Perna NT, Plunkett G, 3rd, Burland V, Mau B, Glasner JD, et al. (2001)
Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409:
529–533.
14. Croxen MA, Finlay BB (2010) Molecular mechanisms of Escherichia coli
pathogenicity. Nat Rev Micro 8: 26–38.
15. Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nature
Reviews Microbiology 2: 123–139.
16. Knutton S, Lloyd DR, McNeish AS (1987) Adhesion of enteropathogenic
Escherichia coli to human intestinal enterocytes and cultured human intestinal
mucosa. Infect Immun 55: 69–77.
17. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB (1995) A genetic locus of
enterocyte effacement conserved among diverse enterobacterial pathogens. Proc
Natl Acad Sci U S A 92: 1664–1668.
18. Garmendia J, Frankel G, Crepin VF (2005) Enteropathogenic and enterohe-
morrhagic Escherichia coli infections: translocation, translocation, translocation.
Infect Immun 73: 2573–2585.
19. Cornelis GR (2006) The type III secretion injectisome. Nat Rev Microbiol 4:
811–825.
20. Galan JE, Wolf-Watz H (2006) Protein delivery into eukaryotic cells by type III
secretion machines. Nature 444: 567–573.
21. Knutton S, Rosenshine I, Pallen MJ, Nisan I, Neves BC, et al. (1998) A novel
EspA-associated surface organelle of enteropathogenic Escherichia coli involved in
protein translocation into epithelial cells. Embo J 17: 2166–2176.
22. Munera D, Crepin VF, Marches O, Frankel G (2010) The N-terminal type III
secretion signal of enteropathogenic E. coli translocator proteins. J Bacteriol 192:
3534–3539.
23. Ru ¨ssmann H, Shams H, Poblete F, Fu Y, Galan JE, et al. (1998) Delivery of
epitopes by the Salmonella type III secretion system for vaccine development.
Science 281: 565–568.
24. Ru ¨ssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, et al. (2003)
Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-
specific CD4 and CD8 T-cell induction. Infect Immun 71: 3463–3472.
25. Sory MP, Boland A, Lambermont I, Cornelis GR (1995) Identification of the
YopE and YopH domains required for secretion and internalization into the
cytosol of macrophages, using the cyaA gene fusion approach. Proc Natl Acad
Sci U S A 92: 11998–12002.
26. Charpentier X, Oswald E (2004) Identification of the secretion and translocation
domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector
Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter.
J Bacteriol 186: 5486–5495.
27. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, et al.
(1998) Potent enzyme inhibitors derived from dromedary heavy-chain
antibodies. Embo J 17: 3512–3520.
28. Fraile S, Munoz A, de Lorenzo V, Fernandez LA (2004) Secretion of proteins
with dimerization capacity by the haemolysin type I transport system of
Escherichia coli. Mol Microbiol 53: 1109–1121.
29. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, et al.
(2008) A versatile nanotrap for biochemical and functional studies with
fluorescent fusion proteins. Mol Cell Proteomics 7: 282–289.
30. Zarivach R, Vuckovic M, Deng W, Finlay BB, Strynadka NC (2007) Structural
analysis of a prototypical ATPase from the type III secretion system. Nat Struct
Mol Biol 14: 131–137.
31. Stein M, Kenny B, Stein MA, Finlay BB (1996) Characterization of EspC, a 110-
kilodalton protein secreted by enteropathogenic Escherichia coli which is
homologous to members of the immunoglobulin A protease-like family of
secreted proteins. J Bacteriol 178: 6546–6554.
32. Heuck AP, Tweten RK, Johnson AE (2003) Assembly and topography of the
prepore complex in cholesterol-dependent cytolysins. J Biol Chem 278:
31218–31225.
33. Palmer M, Harris R, Freytag C, Kehoe M, Tranum-Jensen J, et al. (1998)
Assembly mechanism of the oligomeric streptolysin O pore: the early membrane
lesion is lined by a free edge of the lipid membrane and is extended gradually
during oligomerization. EMBO J 17: 1598–1605.
34. Dean P, Maresca M, Schuller S, Phillips AD, Kenny B (2006) Potent
diarrheagenic mechanism mediated by the cooperative action of three
enteropathogenic Escherichia coli-injected effector proteins. Proc Natl Acad
Sci U S A 103: 1876–1881.
35. Daniell SJ, Kocsis E, Morris E, Knutton S, Booy FP, et al. (2003) 3D structure of
EspA filaments from enteropathogenic Escherichia coli. Mol Microbiol 49:
301–308.
36. Marches O, Covarelli V, Dahan S, Cougoule C, Bhatta P, et al. (2008) EspJ of
enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-
phagocytosis. Cell Microbiol 10: 1104–1115.
37. Whale AD, Hernandes RT, Ooka T, Beutin L, Schuller S, et al. (2007) TccP2-
mediated subversion of actin dynamics by EPEC 2 - a distinct evolutionary
lineage of enteropathogenic Escherichia coli. Microbiology 153: 1743–
1755.
38. Wu Y, Lau B, Smith S, Troyan K, Barnett Foster DE (2004) Enteropathogenic
Escherichia coli Infection Triggers Host Phospholipid Metabolism Perturbations.
Infect Immun 72: 6764–6772.
39. Petty NK, Bulgin R, Crepin VF, Cerdeno-Tarraga AM, Schroeder GN, et al.
(2010) The Citrobacter rodentium Genome Sequence Reveals Convergent Evolution
with Human Pathogenic Escherichia coli. J Bacteriol 192: 525–538.
40. Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP, et al. (1993)
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection.
J Clin Invest 92: 1412–1417.
41. Posfai G, Plunkett G, 3rd, Feher T, Frisch D, Keil GM, et al. (2006) Emergent
properties of reduced-genome Escherichia coli. Science 312: 1044–1046.
42. McDaniel TK, Kaper JB (1997) A cloned pathogenicity island from
enteropathogenic Escherichia coli confers the attaching and effacing phenotype
on E. coli K-12. Mol Microbiol 23: 399–407.
43. Brinkley C, Burland V, Keller R, Rose DJ, Boutin AT, et al. (2006) Nucleotide
sequence analysis of the enteropathogenic Escherichia coli adherence factor
plasmid pMAR7. Infect Immun 74: 5408–5413.
44. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, et al. (2000)
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science
289: 1352–1355.
45. Kru ¨ger C, Hu Y, Pan Q, Marcotte H, Hultberg A, et al. (2002) In situ delivery of
passive immunity by lactobacilli producing single-chain antibodies. Nat
Biotechnol 20: 702–706.
46. Wells JM, Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic
molecules using lactic acid bacteria. Nat Rev Micro 6: 349–362.
47. Lewis GK (2007) Live-attenuated Salmonella as a prototype vaccine vector for
passenger immunogens in humans: are we there yet? Expert Rev Vaccines 6:
431–440.
48. Stritzker J, Pilgrim S, Szalay AA, Goebel W (2008) Prodrug converting enzyme
gene delivery by L. monocytogenes. BMC Cancer 8: 94.
49. Singh R, Paterson Y (2006) Listeria monocytogenes as a vector for tumor-associated
antigens for cancer immunotherapy. Expert Rev Vaccines 5: 541–552.
E. coli Injection of Active sdAbs into Human Cells
PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e1522750. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, et al. (2006) In vivo
antigen delivery by a Salmonella typhimurium type III secretion system for
therapeutic cancer vaccines. J Clin Invest 116: 1946–1954.
51. Cheng CM, Lu YL, Chuang KH, Hung WC, Shiea J, et al. (2008) Tumor-
targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Ther 15:
393–401.
52. Friedlos F, Lehouritis P, Ogilvie L, Hedley D, Davies L, et al. (2008) Attenuated
Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse
melanoma and human breast and colon carcinomas for effective suicide gene
therapy. Clin Cancer Res 14: 4259–4266.
53. Fu W, Lan H, Liang S, Gao T, Ren D (2008) Suicide gene/prodrug therapy
using Salmonella-mediated delivery of Escherichia coli purine nucleoside phosphor-
y l a s eg e n ea n d6 - m e t h o x y p u r i n e2 9-deoxyriboside in murine mammary
carcinoma 4T1 model. Cancer Sci 99: 1172–1179.
54. Zhu X, Zhou P, Cai J, Yang G, Liang S, et al. (2010) Tumor antigen delivered
by Salmonella III secretion protein fused with heat shock protein 70 induces
protection and eradication against murine melanoma. Cancer Sci.
55. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, et al. (2004)
Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli
strain Nissle 1917. J Bacteriol 186: 5432–5441.
56. Henker J, Muller S, Laass MW, Schreiner A, Schulze J (2008) Probiotic
Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of
ulcerative colitis in children and adolescents: an open-label pilot study.
Z Gastroenterol 46: 874–875.
57. Schultz M (2008) Clinical use of E. coli Nissle 1917 in inflammatory bowel
disease. Inflamm Bowel Dis 14: 1012–1018.
58. Andersson P, Engberg I, Lidin-Janson G, Lincoln K, Hull R, et al. (1991)
Persistence of Escherichia coli bacteriuria is not determined by bacterial
adherence. Infect Immun 59: 2915–2921.
59. Sunden F, Hakansson L, Ljunggren E, Wullt B (2006) Bacterial interference–is
deliberate colonization with Escherichia coli 83972 an alternative treatment for
patients with recurrent urinary tract infection? Int J Antimicrob Agents 28 Suppl
1: S26–29.
60. Sunden F, Hakansson L, Ljunggren E, Wullt B (2010) Escherichia coli 83972
bacteriuria protects against recurrent lower urinary tract infections in patients
with incomplete bladder emptying. J Urol 184: 179–185.
61. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, et al. (2007) Tumor-
specific colonization, tissue distribution, and gene induction by probiotic
Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297: 151–162.
62. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat Rev
Cancer.
63. Tanaka T, Williams RL, Rabbitts TH (2007) Tumour prevention by a single
antibody domain targeting the interaction of signal transduction proteins with
RAS. EMBO J 26: 3250–3259.
64. McGonigal K, Tanha J, Palazov E, Li S, Gueorguieva-Owens D, et al. (2009)
Isolation and functional characterization of single domain antibody modulators
of Caspase-3 and apoptosis. Appl Biochem Biotechnol 157: 226–236.
65. Van den Abbeele A, De Clercq S, De Ganck A, De Corte V, Van Loo B, et al.
(2010) A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin
interaction. Cell Mol Life Sci 67: 1519–1535.
66. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D (2010) An
Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal
Œ6-Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production.
Journal of Biological Chemistry 285: 21768–21780.
67. Scheele JS, Rhee JM, Boss GR (1995) Determination of absolute amounts of
GDP and GTP bound to Ras in mammalian cells: comparison of parental and
Ras-overproducing NIH 3T3 fibroblasts. Proceedings of the National Academy
of Sciences of the United States of America 92: 1097–1100.
68. Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW, et al. (2004)
Components of the Cell Death Machine and Drug Sensitivity of the National
Cancer Institute Cell Line Panel. Clinical Cancer Research 10: 6807–6820.
69. Yanish-Perron C, Viera J, Messing J (1985) Improved M13 Phage cloning
vectors and hosts strains: nucleotide sequences of the M13mp18 and pU19
vectors. Gene 33: 103–119.
70. Garmendia J, Phillips AD, Carlier MF, Chong Y, Schuller S, et al. (2004) TccP
is an enterohaemorrhagic Escherichia coli O157:H7 type III effector protein that
couples Tir to the actin-cytoskeleton. Cell Microbiol 6: 1167–1183.
71. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al. (2002)
Short Protocols in Molecular Biology. New York: John Wiley & Sons, Inc..
72. Schlosser-Silverman E, Elgrably-Weiss M, Rosenshine I, Kohen R, Altuvia S
(2000) Characterization of Escherichia coli DNA lesions generated within J774
macrophages. J Bacteriol 182: 5225–5230.
73. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, et al. (2006)
Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat
Methods 3: 887–889.
74. Turner DL, Weintraub H (1994) Expression of achaete-scute homolog 3 in
Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev 8:
1434–1447.
75. Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells:
optimization of critical parameters affecting calcium-phosphate precipitate
formation. Nucleic Acids Res 24: 596–601.
76. Jurado P, Ritz D, Beckwith J, de Lorenzo V, Ferna ´ndez LA (2002) Production of
functional single-chain Fv antibodies in the cytoplasm of Escherichia coli. J Mol
Biol 320: 1–10.
77. Fontana J, Tzeng WP, Calderita G, Fraile-Ramos A, Frey TK, et al. (2007)
Novel replication complex architecture in rubella replicon-transfected cells. Cell
Microbiol 9: 875–890.
E. coli Injection of Active sdAbs into Human Cells
PLoS ONE | www.plosone.org 12 December 2010 | Volume 5 | Issue 12 | e15227